FiercePharma4d
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
thearabianpost4d
Bain Capital Nears Acquisition of Mitsubishi’s Pharma Division in $3.2 Billion Deal
Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group’s pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with ...
Asia Asset Management2d
Has Bain bailed from tussle for Fuji Soft?
The unusually contentious bidding war between US private equity firms Bain Capital and KKR for Tokyo-listed Fuji Soft looks ...
JD Supra4d
Global M&A Trends: Spotlight on Japan
According to a recent KPMG report, the global M&A landscape in 2024 signals a rebound despite challenges like geopolitical tensions, high ...
U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Bloomberg L.P.5d
Bain Is Said to Near €4 Billion Deal for PAI-Backed Apleona
Bain Capital is in advanced talks to acquire German facility management company Apleona Group GmbH in a deal valued at about €4 billion ($4.2 billion), according to people familiar with the matter.
Business Insider5d
Innate Pharma SA (IPHYF) Gets a Hold from Kepler Capital
Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report) on February 12 and set a price target of €3.10. The company’s shares closed last ...